Shares of MannKind Corporation (NASDAQ: MNKD), a biopharmaceutical company focused on inhaled therapeutic products, took a nosedive on November 8, 2024, plummeting by 5.95% in pre-market trading. This sharp decline came despite the company reporting better-than-expected earnings for the third quarter of 2024 the previous day.
While MannKind's Q3 2024 adjusted earnings per share of $0.05 surpassed analysts' estimates of $0.03, the company's revenue performance fell significantly short of expectations. MannKind reported revenue of $19.73 million, a staggering 61.5% lower than the year-ago quarter, missing analysts' projections of $74.50 million.
The primary concern for investors appears to be the underwhelming performance of MannKind's flagship product, Afrezza, an inhaled insulin product for diabetic patients. Afrezza's net revenue grew by a modest 12% year-over-year in Q3 2024, primarily driven by higher demand and improved gross-to-net adjustments. However, the company acknowledged facing headwinds throughout the year, including payers implementing double step edits and a shift in inventory at a major pharmacy chain and one of its specialty pharmacies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.